Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Pyxis Oncology has received a "sell (D-)" rating from Weiss Ratings, indicating concerns over its stock performance.
• The stock's average rating is currently "Hold" with a consensus price target of $7.75, while other brokerages have varying ratings from "buy" to "strong sell."
• Despite recent challenges, Pyxis Oncology reported a quarterly earnings beat with EPS at ($0.30), surpassing estimates by $0.06, and generated $2.82 million in revenue.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also recently weighed in on PYXS. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Zacks Research upgraded shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Wall Street Zen cut shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Friday, October 3rd. Finally, Guggenheim assumed coverage on shares of Pyxis Oncology in a research note on Wednesday, September 3rd. They set a "buy" rating and a $5.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pyxis Oncology presently has an average rating of "Hold" and a consensus price target of $7.75.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $2.91 on Wednesday. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The company has a market cap of $180.47 million, a price-to-earnings ratio of -1.82 and a beta of 1.33. The firm has a fifty day moving average of $1.68 and a 200-day moving average of $1.32.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. Analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd bought a new stake in Pyxis Oncology in the second quarter worth about $26,000. Kingstone Capital Partners Texas LLC bought a new stake in Pyxis Oncology in the second quarter worth about $37,000. XTX Topco Ltd bought a new stake in Pyxis Oncology in the second quarter worth about $40,000. Velan Capital Investment Management LP bought a new stake in Pyxis Oncology in the second quarter worth about $44,000. Finally, Acadian Asset Management LLC bought a new stake in Pyxis Oncology in the first quarter worth about $81,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.